Xeris Biopharma Holdings SG&A Expense (TTM) Insights

Xeris Biopharma Holdings Inc (XERS)

2.87 +0.04 (+1.41%) USD | NASDAQ | Sep 27, 16:00

2.87 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2017. Upgrade now.

Date	Value
June 30, 2024	153.23M
March 31, 2024	150.87M
December 31, 2023	146.10M
September 30, 2023	142.88M
June 30, 2023	140.09M
March 31, 2023	135.44M
December 31, 2022	137.74M
September 30, 2022	157.57M
June 30, 2022	149.61M
March 31, 2022	142.55M
December 31, 2021	125.72M
September 30, 2021	89.54M
June 30, 2021	79.49M
March 31, 2021	71.20M

Date	Value
December 31, 2020	73.73M
September 30, 2020	76.38M
June 30, 2020	74.77M
March 31, 2020	72.15M
December 31, 2019	63.06M
September 30, 2019	51.14M
June 30, 2019	40.92M
March 31, 2019	30.39M
December 31, 2018	21.11M
September 30, 2018	15.49M
June 30, 2018	12.85M
March 31, 2018	9.913M
December 31, 2017	8.015M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

51.14M

Minimum

Sep 2019

157.57M

Maximum

Sep 2022

111.66M

Average

130.58M

Median

SG&A Expense (TTM) Benchmarks